tbuckley/cabot-search huggingface dataset:
Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients age 65 or older.
Authors: Roberto Bordonaro, Giovanni Luca Frassineti, Libero Ciuffreda, Giuseppe Aprile, Anne Thomas, Raghu L. Vishwanath, Chiara Zilocchi, Emmanuelle Dochy, Julien Taïeb, Alberto F. Sobrero
Journal: Journal of Clinical Oncology (2015)

588 Background: The prespecified analysis of patients (pts) ≥65 y in the VELOUR study demonstrated a safety profile similar to that of ziv-aflibercept (Z) (known as aflibercept outside the United States) plus FOLFIRI in the overall VELOUR population. The global ASQoP/AFEQT Program comprises 2 clinical studies (ASQoP [NCT01571284]; AFEQT [NCT01670721]) designed to capture QoL and safety data from a population similar to VELOUR but treated in a real-life setting. We report safety data from the fourth interim analysis of pts ≥65 y. Methods: ASQoP/AFEQT are single-arm, open-label trials evaluating Z in metastatic colorectal cancer pts previously treated with an oxaliplatin-containing regimen. Eligible pts received Z (4 mg/kg) q2w on day 1 of each cycle followed by FOLFIRI until disease progression, unacceptable toxicity, death, or investigator/pt decision. Initial starting doses of FOLFIRI and dose modifications are at treating physician’s discretion. The % of pts ≥65 y with grade (G) 3 or 4 AEs in the combined safety population of ASQoP/AFEQT are compared with the prespecified analysis in pts ≥65 y from the Z + FOLFIRI arm of VELOUR. Results: At data cutoff, the overall safety population comprised 688 pts with ≥1 completed treatment cycle; 303 (44.1%) were ≥65 y. In the overall safety population ≥1 G3/4 AE was reported in 72.2% of pts vs. 83.5% in overall VELOUR. Most G3/4 AEs were G3. There were no reports of G4 hypertension, diarrhea, or fatigue. Median number of cycles was 6 in ASQoP/AFEQT and 9 in the Z + FOLFIRI arm of VELOUR. Table shows summary of AEs in pts ≥65 y. Conclusions: This interim analysis from ASQoP/AFEQT in pts ≥65 y has identified no new safety signals and provides additional safety data suggesting an acceptable toxicity profile in this real-life setting. Clinical trial information: NCT01571284. [Table: see text]
Benzene: Epidemiologic Observations of Leukemia by Cell Type and Adverse Health Effects Associated with Low-Level Exposure
Authors: Peter F. Infante, Mary C. White
Journal: Environmental Health Perspectives (1983)

Benzene has been known to be a bone marrow poison for almost a century. However, it was not until the last decade that benzene's carcinogenic potential was demonstrated by epidemiologic studies. The proposed regulation by the Occupational Safety and Health Administration (OSHA) to lower exposure levels of benzene in the workplace, and the court challenges that followed, have made the evidence of benzene toxicity a frequent topic of discussion and analysis. Epidemiologic evidence of leukemia risk associated with benzene exposure is summarized, including a discussion of certain contentions raised during the OSHA hearing. Special attention is given to information on specific cell types of leukemia associated with benzene and to qualitative and quantitative assessments of health risks associated with low-level benzene exposure.
Prescribing and Treatment in Diseases of Infants and Children
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BCG Vaccination
Authors: Robert C. Partenheimer
Journal: New England Journal of Medicine (1951)

MANY excellent articles and reviews1 , 2 on the different phases of BCG vaccination have appeared in the literature. Since a compilation of the results of these articles was thought to be of interest, the present review was prepared.In 1906 Calmette and Guérin began their experiments in an attempt to find a viable attenuated strain of bovine tubercle bacillus. In 1920, after 250 generations of growth, they finally found a strain that would produce only a localized lesion when injected into an animal. The first attempt at human vaccination with this vaccine was accomplished by Weil-Halle in 1921. Petroff and his . . .
'Critical moment' at hand in HIV/AIDS pandemic, new global strategy to arrest its spread proposed
Authors: M. F. Goldsmith
Journal: JAMA (1992)

MEETING IN Amsterdam, the Netherlands, this week at the VIII International Conference on AIDS, nearly 10 000 delegates from around the world are taking stock of the past decade and looking at the future of the pandemic in a new way. "When we take into account everything we've learned scientifically, in attempts at prevention, and in the experience of fighting this epidemic for 10 years, we realize that the earlier view— which of necessity focused on the virus and on individual behavior that transmits the virus—is too limited," says Jonathan Mann, MD, conference chair. "In fact, it's too limited to succeed." Even as physicians, laboratory and social scientists, and untold numbers of dedicated individuals and groups gave battle, infection with the human immunodeficiency virus (HIV) and death from the acquired immunodeficiency syndrome spread to every part of the globe. It has recently been reported even from such antipodean outliers as
Dialysis or transplantation?
Authors: C. R. Blagg
Journal: JAMA (1983)

Nephrologists are in general agreement that a successful transplant is the optimal treatment for many patients with end-stage renal disease (ESRD). Therefore, the article in this issue ofThe Journalby Terasaki et al (p 1065) describing the improved results of transplantation in recent years with pretransplant blood transfusions is an important one. Nevertheless, in assessing the role of transplantation in the treatment of ESRD, several questions must be addressed. These include the number of patients that can realistically receive transplants, the effectiveness of the procedure, the patient preference for this treatment modality, and the cost. How many patients undergoing dialysis are, in fact, candidates for transplantation? The mean age of patients starting dialysis is now in the middle 50s, yet many consider this to be the upper age limit for transplantation.<sup>1</sup>Therefore, about half the new patients undergoing dialysis in the United States are too old for transplantation.
Dx: sickle cell anemia with iron deficiency Rx: withhold iron!!??
Authors: R. M. Nalbandian
Journal: JAMA (1982)

Thalassemia, a quantitative hemoglobinopathy, plagues more racial groups and victims than the better-publicized qualitative hemoglobinopathy, sickle cell disease. These genetic diseases with their permutations afflict unnumbered millions the world over. The sickle hemoglobin phenotypes in descending order of their prevalence are AS, SS, SC, and S/β-thalassemia. Any physician may encounter one or another of these hemoglobinopathies among his patients. Natta and co-workers discuss in this issue ofThe Journal(p 1442) the differential diagnostic problem presented by two mimetic phenotypes, homozygous S, or sickle cell anemia (SCA), and the doubly heterozygous hemoglobinopathy, S/β-thalassemia. Even more intriguing is the unusual management by these authors of withholding iron therapy in their patient with SCA who was proved conclusively to have iron deficiency, even though an increased incidence of infections may occur in such a patient. An understanding of the<i>current concepts</i>of the sickling event will explain such perplexing management of proved
Adult lactose tolerance
Authors: R. D. McCracken
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
Authors: Clive S. Zent, Betsy R. LaPlant, Brian K Link, Timothy G. Call, Tait D. Shanafelt, Deborah A. Bowen, Neil Kay, George J. Weiner, Thomas E. Witzig
Journal: Blood (2011)
Abstract 3060: Wrap Tightness Determines Rate and Degree of Reverse Ventricular Remodeling with Ventricular Restraint Therapy
Authors: Ravi K Ghanta, Aravind Rangaraj, Ramanan Umakanthan, Lawrence Lee, Minoru Tabata, Rita G Laurence, John A Fox, R. M Bolman, Lawrence H Cohn, Frederick Y Chen
Journal: Circulation (2007)

Objective: We have developed an adjustable and measurable technique of ventricular restraint by placing a fluid-filled epicardial balloon around the entire ventricular surface. Wrap tightness is quantified by measuring balloon luminal pressure at end-diastole. In this study, the effect of wrap tightness on reverse remodeling in a chronic ovine model of HF was assessed. Methods: HF developed in 9 ovine 2 months after ligation of diagonal coronary arteries. Ovine were divided into 3 equal groups: control, low restraint (1.5 mmHg), and high restraint (3.0 mmHg). Epicardial balloons were implanted and ventricular remodeling was evaluated over 2 more months with weekly echocardiography. Wrap tightness was measured weekly via a portacath. Change in LV EF, EDV, and wrap tightness was then assessed using repeated measures analysis of variance. Results: Ventricular restraint decreased EDV and improved EF in all HF ovine. High restraint decreased EDV to a greater degree than low restraint. Wrap tightness decreased as the heart reverse remodeled. Reverse remodeling slowed. Peak reverse remodeling occurred after 21 days with high restraint and after 35 days with low restraint. Conclusion: Ventricular restraint wrap tightness affects the rate and degree of improvement in LV EDV. Periodic adjustment of wrap tightness may be required for optimal restraint therapy efficacy.
Epidemiology and impact of preceding or underlying disease in secondary acute myeloid leukemia
Authors: Lene Sofie Granfeldt Østgård, Bruno C. Medeiros
Journal: HemaSphere (2018)

1Department of Hematology, Aarhus University Hospital, Aarhus, Denmark 2Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark 3Stanford University School of Medicine, Stanford, CA, USA This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CCBY-NC-ND), which allows third parties to download the abstracts and share them with others as long as they credit the author and the abstract book, but they cannot change the content in any way or use them commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
Emphasizing chest pain as a symptom of heart attack
Authors: R. D. Bahr
Journal: JAMA (1993)

<h3>In Reply.</h3> —We agree with Dr Waszak that cesarean sections are frequently performed for fetal indications. Although our article reports on the effect of coverage for uninsured pregnant women on maternal health status and the use of cesarean section, we had previously reported that expanded health coverage was not associated with improved rates of low birth weight or prematurity.<sup>1</sup> We recognize that our data do not permit us to examine the appropriateness of the observed increase in cesarean sections. Nevertheless, our article adds to a growing body of literature that suggests that insurance status may be a determinant of cesarean section use independent of clinical circumstance.<sup>2-4</sup>Further study will be needed to examine prospectively the appropriateness of cesarean section use. Prior studies on the impact of expanded health coverage for low-income pregnant woman have focused solely on infant health outcomes. Our study was intended to be an initial
A rapid test for sickle hemoglobin
Authors: T. Asakura
Journal: JAMA (1975)

Vigorous shaking of oxygenated sickle hemoglobin (Hb S) in solution causes precipitation of the hemoglobin. This unusual property of Hb S forms the basis of a simple test for the presence of Hb S. Comparison of results of this test with those from cellulose acetate electrophoresis in blood samples from 599 patients showed no false-positive or false-negative results. The group tested included 55 persons with sickling disorders and 47 others with unusual hemoglobin patterns. This test may be used to confirm the presence of Hb S or to establish the diagnosis of sickling disorders rapidly in the clinic or at the bedside. (<i>JAMA</i>233:156-157, 1975)
FOOD PREJUDICES AND FOOD FACTS
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Correction
Journal: BMJ (1910)

TMR BN a 78u DEC 3,1190I MEDICO-PSYCHOLOGICAL ASOIAIN.UDICL"T JOUNUS 78 preparing the documents necessary for securing the admission of lunatics into asylums.Magistrates and friends of patients will also find this manual exceedingly helpful.The laws and regulations affecting lunatics being sub- stantially the same in all the provinces of the Indian Empire, the information contained in this book will be of universal value.Flame and Flannelette 2 is the title of a pamphlet issued by the Society for the Prevention of Cruelty to Children, and drawing attention to the many preventable cases of children's deaths from burning.The title is not fully descrip-
Do-not-resuscitate orders in intensive care units. Current practices and recent changes
Authors: R. L. Jayes
Journal: JAMA (1993)

<h3>Objectives.</h3> —To describe the characteristics of patients with do-not-resuscitate (DNR) orders and the frequency and timing of these orders in a representative sample of intensive care units (ICUs) and to compare practices from 1980 to 1990. <h3>Design.</h3> —Prospective inception cohort. <h3>Setting.</h3> —A total of 42 ICUs in 40 US hospitals with 200 or more beds; 26 randomly selected hospitals and 14 large, tertiary care hospitals that volunteered to be studied. <h3>Participants.</h3> —A consecutive sample of 17440 ICU admissions from 1988 to 1990. <h3>Measurements.</h3> —Patient demographic characteristics, comorbid conditions, disease, and physiological abnormalities. <h3>Main Outcome Measures.</h3> —Frequency and timing of DNR orders; ICU resource use before and after DNR orders; and patients' hospital and ICU discharge status. <h3>Results.</h3> —Physicians wrote DNR orders for 1577 ICU admissions (9%) (hospital range, 1.5% to 22%). Patients with ICU DNR orders were older, more functionally impaired, had more comorbid illness, a higher severity of illness, and required the use of more ICU resources compared with patients without DNR orders. Compared with data from a similar survey from 1979 to 1982, ICU DNR orders were more frequent in 1988 to 1990 (9% vs 5.4%;<i>P</i>&lt;.001) and preceded 60% of all in-unit deaths compared with only 39% in 1979 to 1982 (<i>P</i>&lt;.001). Do-not-resuscitate orders were written sooner (for 3.6% vs 2.0% of patients on day 1 in the ICU) and patients with DNR orders remained in the ICU longer in 1988 to 1990 (2.8 vs 1.4 days) than in 1979 to 1982, and had lower ICU and hospital mortality rates (64% vs 74%,<i>P</i>&lt;.001; and 85% vs 94%,<i>P</i>&lt;.001). <h3>Conclusions.</h3> —Over the last decade physicians and patients' families set limits earlier and more frequently in cases likely to have poor outcomes. We attribute this change to a greater dialogue about setting limits to care and a greater knowledge of treatment outcomes among physicians and families. These changes in practice preceded implementation of the Patient Self-determination Act, designed to ensure patient autonomy for decisions about life-sustaining therapy. (<i>JAMA</i>. 1993;270:2213-2217)
Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated in Patients with AP and BP CML and Ph+ ALL.
Authors: Carlo Gambacorti- Passerini, Enrico Maria Pogliani, Michele Baccarani, Giovanni Martinelli, Hagop M Kantarjian, Mammen Chandy, H. Jean Khoury, Dong-Wook Kim, Tim H Brummendorf, Steven Arkin, Jorge Cortes
Journal: Blood (2008)
EDITORIAL
Journal: British Journal of Sports Medicine (1975)

In 1967 the problem of doping in sport was giving many doctors and others cause for concern, and the British Association of Sport and Medicine organised a conference at St. Mary's hospital in April on this topic.The conference proceedings were published, together with other papers on doping but not given at the conference, in the British Journal of Sports Medicine Volume 4, No 2, April 1969.One of the co-editors of those proceedings, Dr. John Williams, concludes his editorial: "There is of course, one other relevant issue still to be sorted out, and that is the issue of Anabolic Steroids, but that is another story . .."At the time of the conference, and subsequently at the time of publication of the Proceedings, it was understood that the anabolic steroid usage was confined to a few "heavy event" athletes, few of course being British; little was known of the benefits or dangers; no tests were available, so there was no mechanism for enforcement of any regulation of this form of doping.In the past few years, developments in complicated biochemical techniques, increasing awareness of the hazards of overdosage of hormones, and a spread of the use of steroids by athletes, have justified this Association in organising another symposium on doping, this time devoted to the use, abuse and detection of anabolic steroids in sport.The symposium took place at the Royal Society of Medicine on February 19th, 1975, and this number of the British Journal of Sports Medicine is devoted entirely to the Proceedings of this meeting.This year's symposium attracted attention from several countries, and a dozen delegates arrived from Belgium, as well as representatives from Denmark, France, Germany, Hungary, Italy, Netherlands, Romania, Spain, Sweden, U.S.A., U.S.S.R., and Yugoslavia; there was a fairly good turn-out from the United Kingdom.The symposium was organised in three sections: Metabolic effects; practical experience; Anabolic detection and enforcement.Ten communications were presented, and a general discussion followed the papers.The manuscripts of the main papers were edited, and the proofs corrected by the authors.A tape-recording was made of the discussion, and the transcription edited where necessary, but without losing the sense of any question or its answer.With over sixty questions, answers and comments, the return of the proofs of the discussion to each speaker for correction was impractical, but every care has been taken to ensure as accurate reporting as possible.
Bulbar Poliomyelitis
Authors: Max J. Fox, J. F. Kuzma, C. L. Junkerman
Journal: New England Journal of Medicine (1952)

THIS report is an analysis primarily of the incidence and prognosis of the various syndromes usually grouped together under the general term "bulbar poliomyelitis." The bulbar forms of acute poliomyelitis account for most of the deaths in the disease; therefore, an important approach to the reduction of the mortality rate is through better understanding of these forms. For this reason, reports1 2 3 on the Minnesota epidemic of 1946 divided the bulbar forms into various subdivisions and suggested that they consisted of not one but several distinct clinical and pathological entities. Since rational therapy must depend on the type of bulbar involvement . . .
Controlled release systems for DNA delivery
Authors: A PANNIER
Journal: Molecular Therapy (2004)

Adapting controlled release technologies to the delivery of DNA has the potential to overcome extracellular barriers that limit gene therapy. Controlled release systems can enhance gene delivery and increase the extent and duration of transgene expression relative to more traditional delivery methods (e.g., injection). These systems typically deliver vectors locally, which can avoid distribution to distant tissues, decrease toxicity to nontarget cells, and reduce the immune response to the vector. Delivery vehicles for controlled release are fabricated from natural and synthetic polymers, which function either by releasing the vector into the local tissue environment or by maintaining the vector at the polymer surface. Vector release or binding is regulated by the effective affinity of the vector for the polymer, which depends upon the strength of molecular interactions. These interactions occur through nonspecific binding based on vector and polymer composition or through the incorporation of complementary binding sites (e.g., biotin–avidin). This review examines the delivery of nonviral and viral vectors from natural and synthetic polymers and presents opportunities for continuing developments to increase their applicability.